Form 4: Nautilus Biotechnology Director Matthew L. Posard Reports Stock Option Grant

Director Matthew L. Posard reports the acquisition of stock options in Nautilus Biotechnology, Inc.

Summary

• On June 14, 2024, Matthew L. Posard, a director of Nautilus Biotechnology, Inc., was granted stock options to purchase 45,000 shares of common stock.
• The exercise price of these options is $2.56 per share.
• The options vest monthly over a period of one year, contingent upon Posard's continuous service as a 'Service Provider' as defined in the Issuer's 2021 Equity Incentive Plan.
• The options expire on June 14, 2034.

Sentiment

Score: 7

Explanation: The sentiment is neutral to slightly positive. The granting of stock options is a standard practice and suggests confidence in the company's future performance, but it's not a major event.

Positives

• The grant of stock options aligns the director's interests with those of the shareholders, incentivizing him to work towards the company's success.
• The vesting schedule encourages long-term commitment from the director.

Risks

• The value of the stock options is dependent on the future performance of Nautilus Biotechnology's stock price.
• If the director ceases to be a 'Service Provider', the unvested options will be forfeited.

Future Outlook

The document does not contain specific forward-looking statements beyond the vesting schedule of the stock options.

Industry Context

Stock option grants are a common form of executive compensation in the biotechnology industry, used to attract and retain talent and align their interests with those of shareholders.

Comparison to Industry Standards

• Stock option grants are a standard component of compensation packages for directors and executives in publicly traded companies, particularly in the biotechnology sector.
• The vesting schedule and exercise price are typical for such grants, designed to incentivize long-term performance and align with shareholder value creation.
• Comparable companies in the biotechnology industry, such as Illumina or Pacific Biosciences, also utilize stock options as part of their executive compensation packages.

Stakeholder Impact

• Shareholders may view the stock option grant positively as it aligns the director's interests with theirs.
• Employees may see it as a sign of the company's commitment to its leadership.

Key Dates